Labcorp Clinical Research Unit
Dallas, Texas, 75247, United States
NCT Number: NCT05306379
A single-center, open-label, Phase 1, drug-drug interaction study to investigate the effect of voclosporin on the pharmacokinetics of simvastatin and simvastatin acid in healthy volunteers.
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 1
Dallas, Texas, 75247, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Oral dose 40 mg
Oral dose 23.7 mg twice daily
Time frame: 9 days
To evaluate the potential effect of multiple oral doses of voclosporin on the single-dose PK of simvastatin and the active metabolite simvastatin acid. Maximum observed concentration (Cmax).
Time frame: 9 days
To evaluate the potential effect of multiple oral doses of voclosporin on the single-dose PK of simvastatin and the active metabolite simvastatin acid. Area under the concentration-time curve (AUC) from time zero to infinity.
Time frame: 9 days
To evaluate the potential effect of multiple oral doses of voclosporin on the single-dose PK of simvastatin and the active metabolite simvastatin acid. Area under the concentration-time curve (AUC) time zero to last quantifiable concentration.
Time frame: 9 days
To evaluate voclosporin blood concentrations - Cmax.
Time frame: 9 days
To evaluate voclosporin blood concentrations - AUC from time zero to 12 hours.
Time frame: 9 days
To evaluate voclosporin blood concentrations - Time to reach maximum observed plasma concentration (Tmax).
Time frame: 9 days
To evaluate voclosporin blood concentrations - Trough concentration (Ctrough) at the end of a dosing interval at steady state.
Time frame: 9 days
To evaluate voclosporin blood concentrations - apparent clearance (CL/F).
Time frame: Up to 2 weeks
Number of subjects with abnormal laboratory test results (eg., hematology, biochemistry and urinalysis) will be assessed
Time frame: Up to 2 weeks
Number of participants with abnormal vital signs (eg., blood pressure, heart rate, body temperature, respiratory rate) will be assessed
Time frame: Up to 2 weeks
Standard 12-lead electrocardiograms (eg., QTcF interval) will be summarized by observed value and change from baseline values.
Aurinia Pharmaceuticals Inc.
Industry
A Single Center, Open Label, Phase 1 Drug-Drug Interaction Study to Investigate the Effects of Voclosporin on the Pharmacokinetics of Simvastatin in Healthy Volunteers
Acronym: Statin-DDI
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07068841
Drug-drug Interaction, Omeprazole Enteric-coated Capsules
Bengbu, Anhui, China
View Trial DetailsNCT04669678
Blood-Borne Infections, Communicable Diseases
Johannesburg, South Africa
View Trial DetailsNCT04487145
Blood-Borne Infections, Communicable Diseases
Masafu, Busia, Uganda
View Trial DetailsNCT05492318
Drug-drug Interaction, Heathy Volunteer
Porto, Portugal
View Trial Details